Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

GNPX

Genprex Inc

May 17 • 04:00PM ET

2.55

Dollar change +0.13
Percentage change 5.37	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.18	Insider Own	2.28%	Shs Outstand	2.10M	Perf Week	9.91%
Market Cap	5.35M	Forward P/E	-	EPS next Y	-2.71	Insider Trans	0.00%	Shs Float	2.05M	Perf Month	14.90%
Income	-27.63M	PEG	-	EPS next Q	-3.69	Inst Own	6.84%	Short Float	2.44%	Perf Quarter	-42.05%
Sales	0.00M	P/S	-	EPS this Y	74.73%	Inst Trans	28.32%	Short Ratio	0.94	Perf Half Y	-75.48%
Book/sh	4.55	P/B	0.56	EPS next Y	52.46%	ROA	-153.97%	Short Interest	0.05M	Perf Year	-91.74%
Cash/sh	3.91	P/C	0.65	EPS next 5Y	-	ROE	-202.83%	52W Range	2.09 - 42.40	Perf YTD	-72.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.89%	ROI	-315.49%	52W High	-93.99%	Beta	-0.60
Dividend TTM	-	Quick Ratio	2.42	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.01%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	2.42	EPS Y/Y TTM	14.61%	Oper. Margin	0.00%	RSI (14)	49.94	Volatility	13.35% 11.27%
Employees	26	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	50.43%	Payout	-	Rel Volume	0.42	Prev Close	2.42
Sales Surprise	-	EPS Surprise	6.20%	Sales Q/Q	-	Earnings	-	Avg Volume	53.16K	Price	2.55
SMA20	8.92%	SMA50	-10.79%	SMA200	-74.34%	Trades		Volume	22,462	Change	5.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-21	Initiated	National Securities	Buy	$7
Apr-29-19	Initiated	Noble Capital Markets	Outperform	$5

May-15-24 04:42AM	Genprex dosing subjects in trial of combination therapy for small-cell lung cancer (Clinical Trials Arena)
May-14-24 08:31AM	Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +7.53%
May-13-24 08:31AM	Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors (PR Newswire)
May-08-24 06:08PM	Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner (PR Newswire) -6.05%
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) -5.13%
08:31AM	Loading…
May-01-24 08:31AM	Genprex to Present and Participate at Upcoming May Investor and Industry Conferences (PR Newswire)
Apr-09-24 08:31AM	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 08:57AM	Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up (Zacks)
Apr-03-24 08:31AM	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +9.51%
Apr-02-24 08:31AM	Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System (PR Newswire)
Mar-22-24 04:10PM	Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Mar-19-24 01:24PM	Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.36%
Mar-12-24 09:01AM	Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers (PR Newswire) -10.43%
Mar-06-24 08:30AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire) +6.31%
Feb-07-24 08:15AM	Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators (PR Newswire) -11.17%
07:30AM	Loading…
Feb-06-24 07:30AM	Genprex to Present at Upcoming BIO CEO & Investor Conference (PR Newswire) -10.45%
Feb-05-24 07:30AM	Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer (PR Newswire) +13.37%
Jan-31-24 08:42AM	Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 (PR Newswire) -29.13%
Jan-05-24 07:00AM	Genprex Provides Business Update and Outlook for 2024 (PR Newswire)
Nov-23-23 08:30AM	Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer (NewMediaWire)
Nov-03-23 09:00AM	Genprex to Present at BIO-Europe 2023 (NewMediaWire) +27.29%
Nov-01-23 07:30AM	Genprex to Present at BIO-Europe 2023 Conference (PR Newswire)
Oct-20-23 03:00PM	Genprex Schedules, Hosts Virtual Key Opinion Leader Event (NewMediaWire)
07:30AM	Genprex to Host a Virtual Key Opinion Leader Event on 'Bringing Gene Therapy to the Fight Against Lung Cancers' (PR Newswire)
Oct-06-23 09:00AM	Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference (NewMediaWire)
Oct-04-23 12:00PM	Genprex to Present Data on the Use of REQORSA for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.11%
Sep-21-23 08:30AM	Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC (GlobeNewswire)
Sep-19-23 09:00AM	Genprex Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations (NewMediaWire)
Sep-08-23 08:00PM	Genprex to Present at Upcoming H.C. Wainwright Conference (NewMediaWire) +6.72%
Sep-07-23 07:30AM	Genprex to Present at Upcoming September Investor Conference (PR Newswire)
12:00PM	Loading…
Sep-04-23 12:00PM	GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-01-23 09:20PM	Genprex Secures Patent Protection in 'Some of the Most Important Markets in the World' (NewMediaWire)
Aug-31-23 12:44AM	Genprex Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation (NewMediaWire)
Aug-24-23 12:25AM	Genprex Appoints Regulatory Expert as It Drives Clinical Programs Forward (NewMediaWire)
Aug-23-23 02:06AM	5 big analyst cuts: BofA sees 'increased risks' for Dick's Sporting Goods (Investing.com) -5.20%
Aug-22-23 07:30AM	Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs (PR Newswire) +7.86%
Aug-13-23 10:24AM	Genprex Granted FDA Orphan Drug Designation for REQORSA(R) for SCLC (NewMediaWire)
Aug-10-23 07:30AM	Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer (PR Newswire)
Aug-08-23 01:04AM	Genprex's Third Fast Track Designation Validates REQORSA(R)'s Potential (NewMediaWire)
Jul-28-23 08:00PM	Genprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China (NewMediaWire) +5.92%
Jul-25-23 01:22AM	Genprex Inc. Closes on $7.5M Registered Direct Offering (NewMediaWire)
Jul-21-23 04:15PM	Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
12:57AM	Genprex Inc. Announces $7.5M Registered Direct Offering (NewMediaWire)
Jul-20-23 01:05AM	Genprex Enters Exclusive License Agreement with University of Pittsburgh (NewMediaWire)
Jul-19-23 08:00AM	Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.31%
12:37AM	Genprex Positioned to Expand Clinical Pipeline (NewMediaWire)
Jul-18-23 08:37AM	Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh (PR Newswire) +10.93%
Jul-12-23 01:00AM	Genprex Reports Positive Results From Phase 1 Acclaim-1 Clinical Trial (NewMediaWire) -8.95%
Jul-07-23 09:00PM	Genprex's Unique Treatment Paradigm Featured in Bell2Bell Podcast (NewMediaWire)
Jul-06-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc. (GlobeNewswire) -7.78%
12:51AM	Genprex Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination (NewMediaWire)
Jul-05-23 08:35AM	Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers (PR Newswire)
Jun-29-23 09:03PM	Genprex Receives Fast Track Designation for Immunogene Therapy (NewMediaWire)
Jun-28-23 08:35AM	Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer (PR Newswire) +6.50%
Jun-02-23 10:15AM	Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial (ACCESSWIRE) +11.35%
Jun-01-23 11:59AM	Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study (Zacks) +8.45%
May-31-23 12:59AM	Genprex Receives Approval to Advance to Phase 2 of REQORSA(R) Trial (NewMediaWire) +7.22%
May-30-23 07:30AM	Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer (PR Newswire) -9.75%
May-26-23 06:00PM	Genprex Announces Results of Phase 1 Trial Will Be Published at ASCO Meeting (NewMediaWire)
May-25-23 05:00PM	Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting (PR Newswire) +8.99%
May-23-23 07:30AM	Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System (PR Newswire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 07:30AM	Genprex to Participate and Present at Upcoming May Industry and Investor Conferences (PR Newswire)
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-19-23 09:11AM	Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting (PR Newswire)
Apr-18-23 09:11AM	Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma (PR Newswire)
Apr-03-23 06:12AM	Is Genprex (NASDAQ:GNPX) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-23-23 07:30AM	Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies (PR Newswire)
Mar-13-23 07:30AM	Genprex to Present at Bioprocessing Summit Conference (PR Newswire)
Mar-08-23 07:30AM	Genprex to Participate in March Investor and Industry Conferences (PR Newswire)
Feb-27-23 08:30AM	Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor (PR Newswire) -14.71%
Feb-23-23 07:00AM	Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023 (PR Newswire) -15.24%
Jan-05-23 07:00AM	Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh (PR Newswire)
Jan-04-23 07:00AM	Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes (PR Newswire) +9.43%
Dec-15-22 07:00AM	Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh (PR Newswire)
Dec-14-22 07:00AM	Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Dec-02-22 08:15AM	Genprex to Present at Upcoming December Investor Conference (PR Newswire)
Oct-24-22 09:45AM	We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate (Simply Wall St.)
Oct-07-22 07:45AM	Genprex to Present at Upcoming October Investor and Industry Conferences (PR Newswire)
Sep-08-22 08:15AM	Genprex to Present at Upcoming September Investor Conference (PR Newswire)
Aug-16-22 07:00AM	Genprex Announces U.S. Patent for REQORSA Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers (PR Newswire) +6.70%
Aug-15-22 07:00AM	Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA in Combination with Tagrisso® in Non-Small Cell Lung Cancer (PR Newswire) +18.08%
Jul-13-22 07:00AM	Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit (PR Newswire)
Jun-02-22 07:00AM	Genprex to Present at Upcoming June Investor Conferences (PR Newswire)
May-19-22 08:15AM	Genprex to Present at Upcoming Investor Conference in May 2022 (PR Newswire)
May-17-22 08:23AM	Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation (Simply Wall St.)
May-09-22 08:15AM	Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference (PR Newswire) -9.80%
May-05-22 08:30AM	Genprex Issues Shareholder Letter and Provides 2022 Corporate Update (PR Newswire)
Apr-18-22 08:15AM	Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022 (PR Newswire) -8.04%
Mar-31-22 07:05AM	Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer (Business Wire)
Mar-23-22 08:00AM	Genprex to Participate in Upcoming Investor Conference in March (Business Wire)
Mar-14-22 04:48AM	How to Profit From Solar Energy (Investopedia) -5.69%
Mar-02-22 08:00AM	Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer (Business Wire)
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 (GlobeNewswire) +7.27%
Feb-09-22 08:15AM	Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes (Business Wire)
Jan-31-22 12:04PM	This Biotech Company Has Cancer and Diabetes Treatments in Development (TheStreet.com) +8.74%
Jan-27-22 11:23AM	Preclinical Data Show Potential for Use of Genprexs ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer (Business Wire)
Jan-24-22 07:09AM	JinkoSolar's Subsidiary Jinko Solar Co., Ltd. to be Listed on Shanghai Stock Exchange on January 26, 2022 (PR Newswire)
Jan-10-22 09:17AM	Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA Systemic Gene Therapy in Non-Small Cell Lung Cancer (Business Wire) +6.31%
08:34AM	Sweihan PV Power Company PJSC -- Moody's assigns Baa1 rating to 881MW Noor Abu Dhabi solar PV project; outlook stable (Moody's)

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNPX

Genprex Inc

Upgrade your FINVIZ experience